Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vesicle Therapeutics, Inc.
Niwot, Colorado, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
Vesicle Therapeutics has demonstrated preclinical efficacy in animal models using their proprietary extracellular vesicle-based platform to deliver gene-editing therapies targeting GPR146 for lipid lowering in hoFH. They are also developing neurotropic gectosomes as a CNS gene delivery system. No human clinical results reported yet.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Extracellular vesicles (programmable delivery vehicles)Gene editing tools (e.g., CRISPR/Cas13a)Nucleic acids/therapeutic nucleic acids
- Industry
- Biotech
Beyond the preview
Go deeper on Vesicle Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vesicle Therapeutics, Inc..